Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Cuvposa Generic Name & Formulations
Legal Class
Rx
General Description
Glycopyrrolate 1mg/5mL; oral soln; cherry-flavored.
Pharmacological Class
Anticholinergic.
How Supplied
Soln—16oz
Manufacturer
Generic Availability
YES
Cuvposa Indications
Indications
To reduce chronic severe drooling in patients 3–16yrs of age with neurologic conditions associated with problem drooling (eg, cerebral palsy).
Cuvposa Dosage and Administration
Adult
Not applicable.
Children
<3yrs: not recommended. Use accurate measuring device. Take on empty stomach. 3–16yrs: initially 0.02mg/kg 3 times daily; may titrate in increments of 0.02mg/kg every 5–7 days based on response and adverse reactions. Max 0.1mg/kg 3 times daily, not to exceed 1.5–3mg per dose based upon weight. See full labeling.
Cuvposa Contraindications
Contraindications
Conditions that preclude anticholinergic therapy (eg, glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon, myasthenia gravis). Concomitant potassium chloride solid oral dosage forms (passage through GI may be arrested or delayed).
Cuvposa Boxed Warnings
Not Applicable
Cuvposa Warnings/Precautions
Warnings/Precautions
Monitor for constipation esp. within 4–5 days of initial dosing or after dose increase. Discontinue if incomplete mechanical intestinal obstruction develops (diarrhea may be early symptom). Autonomic neuropathy. Renal impairment. Ulcerative colitis (esp. large doses). Hyperthyroidism. Cardiovascular disease. CHF. Arrhythmias. Tachycardia. Hypertension. Hiatal hernia associated with reflux esophagitis. Avoid high environmental temperature. Pregnancy (Cat.C). Nursing mothers.
Cuvposa Pharmacokinetics
See Literature
Cuvposa Interactions
Interactions
See Contraindications. May potentiate digoxin slow dissolution oral tabs; monitor and consider using other forms (eg, elixir, caps). Additive antichlolinergic effects with amantadine; consider reducing glycopyrrolate dose. May potentiate atenolol, metformin; consider dose reduction. May antagonize haloperidol (closely monitor or avoid), levodopa (consider increasing dose).
Cuvposa Adverse Reactions
Adverse Reactions
Dry mouth, vomiting, constipation, flushing, nasal congestion; drowsiness, blurred vision, intestinal pseudo-obstruction, mechanical intestinal obstruction.
Cuvposa Clinical Trials
See Literature
Cuvposa Note
Not Applicable
Cuvposa Patient Counseling
See Literature
Images
